Response to 'Do different treatment strategies of galcanezumab have similar effect on migraine?'

Goadsby, P.J.; Terwindt, G.M.; Ruff, D.D.; Ford, J.H.; Tockhorn-Heidenreich, A.; Stauffer, V.L.; ... ; Aurora, S.K. (2020)

Article / Letter to editor

• calcitonin gene-related peptide
• episodic migraine
• Galcanezumab
• LY2951742
• phase 3
• preventive failure

• All authors: Goadsby, P.J.; Terwindt, G.M.; Ruff, D.D.; Ford, J.H.; Tockhorn-Heidenreich, A.; Stauffer, V.L.; Govindan, S.; Aurora, S.K.
• Date: 2020-03-02
• Volume: 27
• Issue: 5
• Pages: e25 - e25
• DOI: doi:10.1111/ene.14168